Physician profile
John Given
NPI 1588779748
$2,208.83
in general payments reported to CMS, 2019-2025
24 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,786 · 2020: $423.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $335.12 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $258.14 | 2019-2020 | |
| Genzyme Corporation | $202.63 | 2019-2020 | |
| Fisher & Paykel Healthcare INC | $196.00 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $189.15 | 2019 | |
| Ironshore Pharmaceuticals INC. | $125.26 | 2019 | |
| Emd Serono, INC. | $111.58 | 2019 | |
| Ucb, INC. | $99.99 | 2019 | |
| Novartis Pharmaceuticals Corporation | $91.80 | 2019-2020 | |
| Genentech USA, INC. | $85.41 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $81.79 | 2019 | |
| Optinose US, INC. | $76.69 | 2019-2020 | |
| Mylan Specialty L.P. | $75.00 | 2019-2020 | |
| Jazz Pharmaceuticals INC. | $72.28 | 2019-2020 | |
| Sunovion Pharmaceuticals INC. | $64.92 | 2019 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alk-Abello, INC | $32.74 | 2019 | |
| Pfizer INC. | $27.98 | 2019-2020 | |
| Grifols USA, LLC | $18.34 | 2019 | |
| Insmed, INC. | $17.58 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $14.18 | 2019 | |
| Merck Sharp & Dohme LLC | $11.54 | 2019 | |
| Circassia INC. | $10.80 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $9.91 | 2020 |
1 company reported research payments only; those appear in the research section below.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Given listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.